Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06522919
Title	Sequential Immunochemotherapy Treatment With Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer (CombiCoR-Vax)
Acronym	CombiCoR-Vax
Recruitment	Not yet recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Indications	colorectal cancer
Therapies	Bevacizumab + Trifluridine-tipiracil hydrochloride Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	ITA